and monocytes (3) , and plays a critical role in both angiogenesis and vasculogenesis (8, 20, 48, 49, 76) .
Numerous investigators have confirmed the importance of VEGF during normal vascular development (8, 20, 49, 76) , and it has also received attention in pathological processes such as ischemia, primarily because of its angiogenic activity. Increased expression of VEGF (31, 46) and its endothelial cell receptors fmslike receptor tyrosine kinase and kinase insert domaincontaining receptor/fetal liver kinase-1 (KDR/flk-1) (46) has been demonstrated acutely after cardiac (31, 46) and cerebral (42) ischemia in animal models, and it was recently shown that serum levels of VEGF increased in patients with active myocardial ischemia then decreased within 30 min of intervention to recanalize occluded vessels (62) . The stimulus for increased VEGF expression during ischemia of organs of the systemic circulation is thought to be hypoxia (42, 68) .
One of the hallmarks of acute pulmonary ischemic injury is increased vascular permeability (5, 6, 30, 41) , and neovascularization occurs after longer periods of unilateral pulmonary arterial ischemia in vivo (10, 47) . Despite similarities that exist with ischemia-reperfusion injury in other solid organs, the mechanisms of ischemic lung injury are likely to be distinct. One important difference between systemic and pulmonary ischemia is that pulmonary ischemia is not necessarily associated with tissue hypoxia if the lung is inflated with oxygen while blood flow is impaired, as is the case, for example, with lung preservation for human lung transplantation. Our laboratory (5, 6) and others (30) previously demonstrated that the vascular injury that occurs in the ischemic pulmonary vasculature is independent of hypoxia.
Our laboratory (7, 38) also recently demonstrated oxygen-independent upregulation of VEGF in association with increased pulmonary vascular permeability during both global ischemia of isolated lungs and unilateral pulmonary arterial occlusion in vivo. To further evaluate the potential role of VEGF during lung ischemia, we developed a model to study the mechanisms of VEGF-mediated endothelial barrier dysfunction in vitro and compared the effects of VEGF on pulmonary endothelial permeability and migration, two possible physiological consequences of increased VEGF expression during ischemia. The pathways by which VEGF mediates cell proliferation (29, 34, 43, 54, 56, 65) and migration (28, 36, 51, 58) have been characterized in some detail, whereas the signaling pathways leading to enhanced endothelial cell permeability have been less extensively evaluated (9, 13, 40, 73) . We explored the role of mitogen-activated protein kinases (MAPKs) in differentially mediating VEGF-induced pulmonary vascular endothelial barrier dysfunction and chemotaxis because both extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 are activated by VEGF and are involved in VEGF-mediated endothelial cell proliferation (43, 54) and migration (28, 60) , respectively.
METHODS

Reagents
Recombinant human VEGF165 (rhVEGF) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The p38 inhibitors SB-202190 and SB-203180, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-290042, the Src kinase inhibitor PP2, the tyrosine kinase inhibitor genistein, and the flk-1 inhibitor SU-1498 were purchased from Calbiochem (San Diego, CA). UO-126 was obtained from Promega (Madison, WI). Rabbit anti-phospho-p44/42 MAPK, rabbit antiphospho-p38 MAPK, and p38 MAPK antibodies were purchased from New England Biolabs (Beverly, MA). Monoclonal anti-pan ERK antibody was obtained from Transduction Laboratories (Lexington, KY). MAPK-activated protein kinase (MAPKAPK)-2 and 27-kDa heat shock protein antibodies were purchased from StressGen (Victoria, BC, Canada). In vitro kinase assay kits for ERK and p38 were purchased from Cell Signaling Technologies (Beverly, MA). Texas Red-phalloidin and SlowFade mounting media were purchased from Molecular Probes (Eugene, OR). Tris-glycine (12%) gels were purchased from Invitrogen (Carlsbad, CA). Transwell chemotaxis chambers (6.5-mm diameter, 8-m pore size) were purchased from Costar (Cambridge, MA). Chemotaxis filters were soaked in 20 g/ml of rat tail collagen (Boehringer Mannheim, Indianapolis, IN) in 0.1% acetic acid for 1 h at room temperature and dried overnight. Triton X was purchased from Bio-Rad (Hercules, CA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.
Bovine pulmonary arterial endothelial cells (BPAECs) frozen at passage 16 were obtained from the American Type Culture Collection (CCL 209; Manassas, VA), cultured in complete medium, and used at passages 19-24, as previously described by our laboratory (22) . Bovine lung microvascular endothelial cells (BLMVECs) at passage 3 were purchased from VEC TECHNOLOGIES (Troy, NY) and were used at passages [5] [6] [7] [8] [9] . All endothelial cell cultures were maintained in DMEM (Life Technologies, Rockville, MD) supplemented with 20% (vol/vol) colostrum-free bovine serum (Irvine Scientific, Santa Ana, CA), 15 g/ml of endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY), 1% antibiotic and antimycotic solution (10,000 U/ml of penicillin, 10 g/ml of streptomycin, 25 g/ml of amphotericin B; KC Biologicals, Lenexa, KS), 0.1 mM nonessential amino acids (Life Technologies), and heparin (1,000 U/ml; Pharmacia and Upjohn, Kalamazoo, MI). The endothelial cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2-95% air and grew to contact-inhibited monolayers with typical cobblestone morphology. Cells from each primary flask were detached with 0.05% trypsin, resuspended in fresh culture medium, and passaged into 35-mm dishes for MAPK phosphorylation and activity determinations, eight-well gold microelectrode chambers for measurement of transendothelial electrical resistance (TER), or Transwell chemotaxis chambers for migration measurements. Cells were washed three times and then transferred to medium (as described above) that did not contain endothelial cell growth supplement and contained only 2% FBS for 22-24 h before initiation of the experimental protocols.
Measurement of TER
The dose-response of pulmonary conduit and microvascular endothelial cells to rhVEGF and the effects of MAPK, PI3K, Src kinase, flk-1, and tyrosine kinase inhibition on VEGF-mediated permeability were assessed by measurement of TER with the use of electric cell-substrate impedance sensing (Applied BioPhysics, Rochester, NY) as previously described by our laboratory (23) . Briefly, cells were seeded onto gold microelectrodes (Applied Biophysics) and grown to confluence. The size of the small gold electrode (Յ10 Ϫ3 cm 2 ) is critical so that the impedance resulting from the presence of cells on the electrode will predominate over the resistance of the medium (27) . Cells were washed three times in lowserum medium as described in Reagents and then were connected to the electric cell-substrate impedance sensing system for measurement of baseline TER. The applied alternating current (1 A) was clamped so that impedance (resistance) was directly related to changes in voltage, which was measured with a locked-in amplifier. Data from the electrical resistance experiments (ohms) were obtained over the experimental time course at 6-min intervals and downloaded to a personal computer for pooling of data for statistical analysis. Resistance values for each microelectrode were normalized as the ratio of measured resistance to baseline resistance and plotted as a function of time. For experiments with inhibitors, the maximal decrease in resistance at a given time after the addition of rhVEGF was compared between groups.
For some experiments, TER was resolved into components reflecting resistance to current flow beneath the cell layer (␣) and resistance to current flow between adjacent cells (R b) (24) with the methods of Giaever and Keese (27) , which model the endothelial monolayer mathematically. This analysis allowed evaluation of the relative contribution of alterations in the net state of cell-matrix adhesion (␣) and cell-cell integrity (R b) to the overall decrease in TER induced by VEGF.
Measurement of Endothelial Cell Chemotaxis
Assessment of endothelial cell migration was performed as recently described (16) with minor modifications. Endothelial cells (bovine macrovascular and microvascular) were dislodged after brief trypsinization and dispersed into homogeneous single-cell suspensions that were washed extensively with medium 199-0.1% acid-free BSA (migration medium) and resuspended in the same medium at 10 6 cells/ml. To assess migration from established monolayers, cells (10 5 ) were dispersed onto collagen-coated chemotaxis filters that partitioned the Transwell inserts into upper and lower chambers. Migration medium (300 l) was placed in the lower chambers, and the cells were allowed to adhere for 1 h at 37°C. In some experiments, the medium on both sides of the filters was replaced with specific antagonists for 30 min after cell attachment. The medium in the lower chambers was then removed, and cells were challenged by the addition of 300 l of fresh migration medium containing chemoattractants to the lower chamber. Unless otherwise indicated, migration was allowed to proceed for 2 h at 37°C. The cells that remained attached to the upper surface of the filters were carefully removed with cotton swabs, and the cells that migrated to the lower surface of the filters were fixed and stained with a Diff-Quik staining set (Dade Behring, Newark, DE) according to the manufacturer's recommendations. The filters were allowed to dry under a vented hood, carefully removed from the Transwell chambers, mounted on glass slides with Cytoseal mounting medium (VWR, Bridgeport, NJ), and finally examined by light microscopy (ϫ200, Nikon Eclipse TE 300). Images of at least six consecutive fields lying horizontally across each filter were captured by a Sony digital photo camera (DKC 5000). The number of migrating cells per field was enumerated, and the average was calculated. Data are expressed as the number of migrating cells per field and represent the mean Ϯ SE values from three separate experiments performed in duplicate within each experiment unless specified otherwise.
Evaluation of Actin Cytoskeletal Rearrangement
Actin cytoskeletal remodeling occurs during cell migration and is intimately linked with endothelial cell barrier regulation (22) . We therefore performed imaging of endothelial gap formation and F-actin organization, as previously described (69), after fixing the endothelial cell monolayers with 5% paraformaldehyde in phosphate-buffered saline containing 25 mM Tris, pH 7, on ice for 10 min. Cells were rinsed thoroughly in Tris-buffered saline (pH 7.6) then permeabilized by treatment with Triton (0.2%) in rinse buffer. After the cells were rinsed three times, they were incubated with 1% BSA in rinse buffer at room temperature for 1 h followed by incubation with 1 U/ml of Texas Red-phalloidin (Molecular Probes) to identify F-actin by fluorescence microscopy. After three washes with PBS, the coverslips were mounted and analyzed with a Nikon video imaging system consisting of a phase-contrast inverted microscope, equipped with a set of objectives and filters for immunofluorescence, connected to a digital camera and processor. The images were recorded and saved on a Pentium II PC for further management with Adobe Photoshop software.
Evaluation of MAPK Activation
Western blot analysis. MAPK activation was determined as previously described (70) by the immunoblotting of endothelial cell lysates with specific phospho-ERK and phospho-p38 antibodies that indicate the enhanced catalytic activity of the enzymes. Briefly, after VEGF challenge, cells were lysed in 2ϫ Laemmli SDS sample buffer and boiled for 5 min. The lysates were separated by 12% SDS-PAGE and electrophoretically transferred to nitrocellulose membranes for Western immunoblotting as our laboratory previously described (70) . ERK1/2 phosphorylation was detected with 1 g/ml of rabbit anti-phospho-p44/42 MAPK; p38 MAPK phosphorylation was determined by rabbit anti-phospho-p38 MAPK (1 g/ml); total ERK protein was detected by monoclonal anti-pan ERK antibody (50 ng/ml); and total p38 MAPK protein was detected by rabbit anti-p38 MAPK antibody (1 g/ml). After incubation with peroxidase-conjugated secondary antibodies (goat anti-rabbit IgG, 1:10,000 dilution; Sigma or goat anti-mouse IgG, 1:10,000 dilution; Bio-Rad), immunoreactive proteins were visualized with an enhanced chemiluminescence detection system according to the manufacturer's directions (Amersham).
In vitro kinase assays. VEGF-mediated activation of p38 and ERK was confirmed with in vitro kinase assays. After exposure to rhVEGF (200 ng/ml), BLMVECs were harvested under nondenaturing conditions, washed with PBS, then lysed in cell lysis buffer (Cell Signaling Technologies) containing phenylmethylsulfonyl fluoride. Phosphorylated p38 was immunoprecipitated with immobilized phospho-p38 MAPK antibody, and then an in vitro kinase assay was performed according to the manufacturer's protocol (Cell Signaling Technologies). Samples were analyzed for p38 kinase activity by Western blot analysis, probing with phosphoactivating transcription factor-2 antibody (Cell Signaling Technologies). To evaluate ERK activation, a p44/42 MAPK assay kit from Cell Signaling Technologies was employed. Briefly, immobilized phospho-p44/42 MAPK antibody was used to selectively immunoprecipitate active ERK1/2 from cell lysates. The resulting immunoprecipitate was then incubated in vitro with an Ets domain protein (Elk)-1 fusion protein in the presence of ATP and kinase buffer per the manufacturer's instructions. Phosphorylation of Elk-1 was assessed by Western blot analysis with a phospho-Elk antibody. The effects of UO-126 on inhibition of ERK1/2 were also confirmed with this assay. Because the pyridinylimidazole compounds inhibit p38 MAPK by complexing with p38 MAPK in the ATP-binding region and do not prevent phosphorylation of p38 (74), the effects of SB-202190 on the activation of p38 in response to VEGF were evaluated by immunoprecipitating the cell lysates with anti-MAPKAPK2 antibody (MAPKAPK2 is activated by p38), immobilizing the immunoprecipitated protein with protein A/G PLUS-agarose (Santa Cruz Biotechnology), then incubating the immunoprecipitates in vitro with 27-kDa heat shock protein (HSP-27), a known MAPKAPK2 substrate, in the presence of kinase buffer (Cell Signaling Technologies) and 5 Ci of ␥-32 P. Activation or inhibition of HSP-27 was then determined by Western blot analysis and autoradiography.
Statistical Analysis
Differences in TER of endothelial cells in response to increasing concentrations of rhVEGF were determined with split-plot analysis of variance. The effects of genistein, SU-1498, MAPK, PI3K, and Src kinase inhibitors on TER were compared with one-way analysis of variance. Differences in cell migration in response to rhVEGF in the presence and absence of pharmacological inhibitors were evaluated with two-way analysis of variance. When significant variance ratios were obtained, least significant differences were calculated to allow comparison of individual group means. Differences were considered significant for P values Յ 0.05.
RESULTS
Effects of VEGF on In Vitro Endothelial Barrier Function and Actin Cytoskeletal Rearrangement
As shown in Fig. 1 , VEGF caused a dose-and timedependent decrease in TER of both BPAECs (A) and BLMVECs (B). Endothelial barrier dysfunction was maximal 30-40 min after VEGF administration, with complete recovery of barrier function in both cell types by 60 min at concentrations of Յ10 ng/ml of rhVEGF. Partial recovery of barrier function was seen with higher VEGF concentrations. The effects of rhVEGF on TER were inhibited by pretreatment of cells with VEGF-neutralizing antibody (Calbiochem) at a 10-fold excess (data not shown). As shown in Fig. 2 , when TER was mathematically partitioned into components reflecting resistance to current flow between adjacent cells (R b ) and resistance to current flow beneath the cell layer (␣) (27) , administration of rhVEGF (200 ng/ ml) to BLMVECs decreased R b substantially without altering ␣, suggesting a primary alteration of cell-cell contact with preserved integrity of cell-matrix adhesion. Alterations in TER of BLMVECs were accompanied by time-dependent actin cytoskeletal remodeling (Fig. 3) characterized by the development of F-actin containing stress fibers and intercellular gap formation 30-60 min after administration of 200 ng/ml of rhVEGF.
Effects of VEGF on Endothelial Cell Chemotaxis
In contrast to transendothelial permeability, the dose response of BPAECs and BLMVECs to rhVEGF differed when endothelial cell chemotaxis was evaluated. Migration of both conduit and microvascular lung endothelial cells was maximal at a VEGF concentration of 10 ng/ml and decreased at higher VEGF concentrations (Fig. 4) . However, the magnitude of endothelial cell chemotaxis in response to rhVEGF was more pronounced in BPAECs compared with that in BLMVECs.
Role of MAPK Activation in VEGF-Induced Barrier Dysfunction, Actin Rearrangement, and Chemotaxis
Administration of permeability-enhancing concentrations of rhVEGF to BLMVECs was also accompanied by activation of both p38 and ERK1/2 MAPK, as demonstrated by both Western blot (Fig. 5 ) and in vitro kinase (Fig. 5) Inhibition of both ERK1/2 and p38 MAPK also attenuated actin stress fiber formation in response to VEGF (200 ng/ml) as shown in Fig. 7 . The effects of MAPK inhibition were confirmed with in vitro kinase assays that demonstrated attenuation of VEGF-mediated ERK activation by UO-126 (Fig. 8A) and p38 activation by SB-202190 (Fig. 8B) . Transendothelial permeability was also attenuated by inhibition of PI3K with LY-290042 (50 M; Fig. 6E ) in this model. Pretreatment with LY-290042 (Fig. 9 ) only minimally decreased activation of ERK but markedly attenuated p38 MAPK activity, suggesting that the effects of PI3K inhibition are primarily via attenuation of downstream p38 MAPK activation in response to VEGF.
As shown in Fig. 10 , the chemotaxis of BPAECs in response to rhVEGF (10 ng/ml) was attenuated by pretreatment with genistein (10 M; A), SU-1498 (10 mM; B), SB-203180 (20 M; C), LY-290042 (50 M; E), and PP2 (10 mM; F), consistent with previous reports that flk-1-mediated p38 activation is an important Fig. 2 . Representative tracing of total electrical resistance resolved into components that reflect resistance to current flow beneath the cell layer (␣) and resistance to current flow between adjacent cells (Rb), using the method of Giaever and Keese (27) , which models the endothelial monolayer mathematically. Administration of rhVEGF (200 ng/ml) to BLMVECs decreased Rb substantially without altering ␣, suggesting preserved integrity of cell-matrix adhesion. component of VEGF-induced endothelial migration (60) . Interestingly, despite the finding that UO-126 inhibited actin stress fiber and interendothelial gap formation in confluent pulmonary microvascular endothelial monolayers exposed to 200 ng/ml of rhVEGF, MEK inhibition did not alter VEGF-mediated endothelial chemotaxis (Fig. 10D) .
DISCUSSION
VEGF, a potent endothelial cell mitogen (39, 45) , has been found to have multiple physiological and pathophysiological effects, including mediation of endothelial barrier dysfunction (13, 18, 19, 33, 40, 59, 71, 73) and its role as a chemotactic factor for both endothelial cells (28, 37, 58) and monocytes (3) . Recent studies have also suggested that VEGF may act as a survival factor for endothelial (21, 26, 72) , hematopoietic (44) , and epithelial (36) cells. VEGF has been shown to play a critical role in normal vascular development (8, 20, 49, 76) and vascular remodeling under a number of pathophysiological circumstances, including ischemia (1, 48) . VEGF is highly expressed in the lung under basal conditions (50) , and studies (14, 25, 55, 67) have suggested a significant role for VEGF in pulmonary vascular remodeling in response to hypoxia, monocrotaline, and congenital heart disease. Our laboratory (7, 38) previously demonstrated oxygen-independent upregulation of VEGF expression in response to ischemia in the ventilated lung and a potential role for VEGF in increased pulmonary vascular permeability under these conditions.
Although the signal transduction pathways leading to VEGF-induced endothelial proliferation and migration have been studied extensively (28, 29, 34, 37, 51, 53, 54, 56, 58, 60) , the cellular mechanisms mediating endothelial barrier dysfunction in response to VEGF have been less thoroughly evaluated (9, 13, 73) . Previous studies have suggested that ERK1/2 and p38 MAPK are key mediators of signal transduction in response to VEGF (53) . Interestingly, both ERK1/2 and p38 MAPK activation have been demonstrated after cardiac (12, 57, 66) and cerebral (64) ischemia or ischemia-reperfusion, and other studies (2, 75) have suggested that these MAPKs may be critical mediators of the injury that occurs in response to ischemia in these organs. The mechanisms by which MAPK inhibition attenuates ischemia-reperfusion injury of systemic organs is incompletely understood but may be linked with the inhibition of inflammatory responses (4) .
As a first step to understanding the potential role of VEGF in ischemic lung injury, we sought to develop an in vitro model to determine how VEGF induces specific pulmonary vascular endothelial responses and to understand whether differential MAPK signaling might be involved in determining these disparate responses. Our studies demonstrate a differential concentration dependence of both conduit and microvascular pulmonary endothelial cells to VEGF when barrier regulatory and chemotactic responses were evaluated. Both large-and small-vessel endothelial cell barrier function, assessed by continuous measurement of TER, declined with increasing concentrations of VEGF. Barrier dysfunction was transient at low concentrations of VEGF (Յ10 ng/ml) but only partially reversible at higher concentrations of VEGF. These data are consistent with previous reports of VEGF-mediated increased endothelial cell permeability in vitro as assessed by histological (18, 19, 59 ) and physiological (9, 13, 33, 40, 71) parameters. Our data extend these previous studies by implicating alterations of cell-cell contact (R b ) rather than endothelial cell detachment from the extracellular matrix (␣) as the cause of endothelial barrier dysfunction induced by VEGF, findings that are consistent with previous reports (13, 18, 40) Fig. 9 . Inhibition of PI3K with LY-290042 markedly attenuated activation of p38 but only minimally attenuated activation of ERK1/2. MAPK activities were evaluated with in vitro kinase assays in which ATF-2 was the substrate for activated p38 and Elk was the substrate for ERK1/2. demonstrating a potential role for endothelial cell junctional protein disorganization in VEGF-mediated enhanced permeability.
When permeability responses to VEGF were compared with the concentration-response curves for endothelial cell chemotaxis to VEGF, there were clear differences not explained by differences in cell type because BPAECs and BLMVECs were used for evaluation of both responses. Chemotaxis was maximal at a VEGF concentration that caused a trivial, reversible decrease in endothelial barrier function (10 ng/ml) and was attenuated at higher VEGF concentrations, strongly suggesting that enhanced endothelial permeability in response to VEGF occurs independently of endothelial cell migration. This finding is consistent with a recent report (49) that high VEGF expression levels during development were linked with vasculogenesis and permeability, whereas lower levels were associated with angiogenesis and cell migration. The dose response of pulmonary vascular endothelial cells to VEGF when evaluating endothelial chemotaxis in our studies is similar to that recently demonstrated by Kanno et al. (37) in human umbilical vein endothelial cells. Those investigators suggested that 10-fold higher concentrations of VEGF were required to maximally induce endothelial cell proliferation, compared with chemotaxis, but did not evaluate the effects of VEGF on permeability. Only one recent study (28) has directly compared the ability of VEGF to mediate endothelial migration and permeability. Although these investigators evaluated chemotaxis both in vitro and in vivo, endothelial barrier function was assessed only with an in vivo assay (Miles assay). This study (28) suggested that stimulation of KDR/flk-1 (VEGF receptor 2) mediated both endothelial chemotaxis and permeability; however, the specific signaling pathways activated by KDR/flk-1 that might explain differential physiological responses were not evaluated. Interestingly, our data suggest that pharmacological inhibition of flk-1 had no significant effect on endothelial barrier dysfunction in vitro in response to VEGF, although it did abolish VEGF-mediated endothelial cell chemotaxis. A recent study by Clauss et al. (11) suggested a permissive role for transmembrane tumor necrosis factor in mediating VEGF-induced hyperpermeability in human umbilical vein endothelial cells and in skin vasculature, raising the possibility that VEGF may initiate cellular signaling via membrane proteins other than its well-characterized endothelial cell receptors, although this study reported expression of transmembrane tumor necrosis factor in normal dermal endothelium but not in lung vasculature.
VEGF has been demonstrated to activate a number of mediators of signal transduction in endothelial cells both in vitro and in vivo (26, 28, 32, 43, 52 ; for summary see Ref. 53 ). Our studies demonstrate that VEGF-mediated endothelial barrier dysfunction was attenuated by inhibition of PI3K, p38 MAPK, or MEK/ ERK. The effects of PI3K inhibition appear to be mediated primarily by inhibition of downstream p38 MAPK activation because VEGF-induced ERK activation was not dramatically altered by PI3K inhibition. Simultaneous administration of both p38 and MEK/ ERK inhibitors did not abolish this protective effect (data not shown), suggesting that activation of p38 is not directly upstream of ERK in a signaling cascade or vice versa. ERK1/2 has been implicated in VEGF-mediated endothelial barrier dysfunction by several investigators (35, 40) , and our laboratory (70) recently demonstrated that the ERK1/2 pathway is a key regulator in the barrier regulatory response of bovine endothelial cells to phorbol esters. The involvement of phospholipase C-␥/protein kinase C in VEGF-induced alterations in permeability has been controversial (9, 13, 40, 73) , and we could not identify previous studies that have addressed a potential role for p38 MAPK in enhanced endothelial permeability in response to VEGF. Our studies suggest that inhibition of either VEGF-mediated ERK1/2 or p38 activation has similar consequences on increased endothelial permeability, a finding not described in other models of endothelial barrier regulation.
As previously reported by others (28, 37, 51, 58, 60) , in contrast to VEGF-mediated barrier dysfunction, endothelial cell chemotaxis in response to VEGF was attenuated by inhibition of tyrosine kinase, flk-1, PI3K, and p38 but not by inhibition of MEK/ERK. Interestingly, inhibition of MEK/ERK failed to prevent VEGF-mediated cell migration despite the finding that actin cytoskeletal remodeling induced by VEGF was attenuated by MEK inhibition. These data provide additional evidence for differential MAPK signaling in VEGF-induced permeability and chemotaxis. Whereas both responses required p38 activation, ERK1/2 activity was only essential in VEGF-mediated endothelial barrier regulation. Our results are consistent with previous reports (37, 60) suggesting that the effects of VEGF on actin stress fiber formation and endothelial cell migration are mediated by independent pathways involving both p38 activation and enhanced actin polymerization as well as phosphorylation of focal adhesion kinase and assembly of focal adhesions. Our studies also confirmed that inhibition of Src kinase, which inhibits focal adhesion assembly, attenuated VEGFmediated endothelial chemotaxis, yet Src kinase inhibition did not alter the permeability response to VEGF. It has been shown that VEGF-mediated endothelial chemotaxis (51, 58) and actin stress fiber formation (51) may also depend on activation of a pathway involving the serine threonine kinase Akt and its downstream effector nitric oxide. Thus cell migration in response to VEGF is likely to result from activation of multiple overlapping pathways, and inhibition of actin stress fiber formation alone is not sufficient to prevent this response.
One potential limitation of these studies may be the use of pharmacological inhibitors to investigate pathways of signal transduction. The pharmacological agents used in the present study were administered at concentrations with well-established in vitro specificity (15, 17) . In addition, the specificity of these drugs for inhibition of p38 and ERK1/2 MAPK in our studies was confirmed with two independent assays (data not shown). Although a pharmacological approach to protein kinase inhibition has been criticized because of possible nonspecific effects of such agents, others have suggested that an adequate picture of signal transduction is best performed in living cells subjected to a minimal amount of manipulation (61) . Furthermore, the use of genetic approaches for modulating signal transduction pathways (e.g., overexpression of dominant negative gene constructs) is limited when evaluating physiological responses such as endothelial permeability because low transfection efficiency and membrane-altering properties of currently available transfection reagents make assessment of barrier properties of transfected cells difficult.
In summary, our studies compare the cellular mechanisms regulating barrier dysfunction and chemotaxis of both conduit and microvascular pulmonary endothelial cells in response to VEGF. The dose-response curves for enhanced permeability and cell migration differed, and these physiological processes involved activation of overlapping but distinct signaling pathways. These data suggest a potential explanation of how VEGF differentially mediates physiological responses in vivo, because concentration-dependent activation of specific signal transduction pathways may determine the balance of effects of VEGF on the vascular endothelium under a number of pathophysiological circumstances, including ischemia. Understanding the cellular mechanisms by which VEGF mediates pulmonary endothelial cell barrier dysfunction and chemotaxis will allow more critical evaluation of the role of this pluripotent growth factor in both normal lung development and ischemic vascular injury and remodeling.
